- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)
(RFA-DA-21-019)
National Institute on Drug Abuse
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
- Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)
(PAR-20-182)
National Institute on Drug Abuse
Application Receipt Date(s): October 30, 2020 - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
(Note: COVID-19 research related to substance abuse and substance use disorders is within scope of this FOA)
National Institute on Drug Abuse
National Cancer Institute
(PAR-19-064)
Application Receipt Date(s): June 8, 2020; October 6, 2020; February 8, 2021; June 8, 2021; October 8, 2021, by 5:00 PM local time of applicant organization
(NOT-HL-20-746)
Key Dates
Release Date: March 27, 2020
First Available Due Date: June 01, 2020
Expiration Date: June 02, 2020
NIDA offers Genotyping to Substance Abuse Disorder Investigators
(NOT-DA-20-041)
Submit requests no later than September 14, 2020
Please direct your request to Jonathan D. Pollock, Ph.D.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment